According to that study, 48.8% of the participants were homozygous for SMN1 deletion, 2.8% were compound heterozygous for a subtle mutation and an SMN1 deletion (thus 51.6% were affected by 5q-SMA), whereas 48.4% remained undiagnosed. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.